prikaz prve stranice dokumenta Association between the COX-2 rs689466 polymorphism and antipsychotic treatment: Impact on HDL cholesterol changes in clozapine-treated psychosis patients
Pristup korisnicima matične ustanove
Znanstveni rad - Izvorni znanstveni rad
Association between the COX-2 rs689466 polymorphism and antipsychotic treatment: Impact on HDL cholesterol changes in clozapine-treated psychosis patients
Prostaglandins, Leukotrienes and Essential Fatty Acids, 204 (2025); 102665. https://doi.org/10.1016/j.plefa.2025.102665
Nadalin, Sergej; Ljoka, Ivan; Savić, Aleksandar; Silić, Ante; Peitl, Vjekoslav; Karlović, Dalibor; Vilibić, Maja; Zatković, Lena; Buretić-Tomljanović, Alena

Citirajte ovaj rad

Nadalin, S., Ljoka, I., Savić, A., Silić, A., Peitl, V., Karlović, D. ... Buretić Tomljanović, A. (2025). Association between the COX-2 rs689466 polymorphism and antipsychotic treatment: Impact on HDL cholesterol changes in clozapine-treated psychosis patients. Prostaglandins, Leukotrienes and Essential Fatty Acids, 204.. doi: 10.1016/j.plefa.2025.102665

Nadalin, Sergej, et al. "Association between the COX-2 rs689466 polymorphism and antipsychotic treatment: Impact on HDL cholesterol changes in clozapine-treated psychosis patients." Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 204, 2025. https://doi.org/10.1016/j.plefa.2025.102665

Nadalin, Sergej, Ivan Ljoka, Aleksandar Savić, Ante Silić, Vjekoslav Peitl, Dalibor Karlović, Maja Vilibić, Lena Zatković i Alena Buretić Tomljanović. "Association between the COX-2 rs689466 polymorphism and antipsychotic treatment: Impact on HDL cholesterol changes in clozapine-treated psychosis patients." Prostaglandins, Leukotrienes and Essential Fatty Acids 204 (2025). https://doi.org/10.1016/j.plefa.2025.102665

Nadalin, S., et al. (2025) 'Association between the COX-2 rs689466 polymorphism and antipsychotic treatment: Impact on HDL cholesterol changes in clozapine-treated psychosis patients', Prostaglandins, Leukotrienes and Essential Fatty Acids, 204. doi: 10.1016/j.plefa.2025.102665

Nadalin S, Ljoka I, Savić A, Silić A, Peitl V, Karlović D, i sur.. Association between the COX-2 rs689466 polymorphism and antipsychotic treatment: Impact on HDL cholesterol changes in clozapine-treated psychosis patients. Prostaglandins, Leukotrienes and Essential Fatty Acids [Internet]. 04.2025. [pristupljeno 11.03.2025.];204. doi: 10.1016/j.plefa.2025.102665

S. Nadalin, et al., "Association between the COX-2 rs689466 polymorphism and antipsychotic treatment: Impact on HDL cholesterol changes in clozapine-treated psychosis patients", Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 204, Travanj 2025. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:570176. [Citirano: 11.03.2025.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:570176
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Association between the COX-2 rs689466 polymorphism and antipsychotic treatment: Impact on HDL cholesterol changes in clozapine-treated psychosis patients
AutorSergej Nadalin
AutorIvan Ljoka
AutorAleksandar Savić
AutorAnte Silić
AutorVjekoslav Peitl
AutorDalibor Karlović
AutorMaja Vilibić
AutorLena Zatković
AutorAlena Buretić-Tomljanović
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za medicinsku biologiju i genetiku)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Psihijatrija
Sažetak (engleski)
Several studies have shown antipsychotic effects of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib as an add-on treatment to antipsychotic treatment. The functional rs689466 (A/G) polymorphism in the gene encoding COX-2 (also known as the prostaglandin-endoperoxide synthase 2 gene) has been correlated with schizophrenia risk and the niacin skin flush response among chronic patients under antipsychotic treatment. Here, we investigated whether this polymorphism was associated with antipsychotic treatment in a group of total psychosis patients (N = 186), as well as a subgroup of patients treated with clozapine (N = 74). Antipsychotic-naïve first-episode patients and non-adherent chronic psychosis patients were genotyped by polymerase chain reaction/restriction fragment length polymorphism analysis. At baseline and after 8 weeks of treatment with various antipsychotic medications, we assessed the patients’ Positive and Negative Syndrome Scale (PANSS) scores, factors, and metabolic syndrome-related parameters, including fasting plasma lipid and glucose levels and body mass index. In the total patient group, the COX-2 polymorphism was not associated with PANSS psychopathology scores or metabolic parameters. However, in the subgroup of patients treated with clozapine, the COX-2 polymorphism was associated with changes in plasma HDL cholesterol. Specifically, compared to patients homozygous for the A allele, the subgroup of patients treated with clozapine and positive for the G allele (i.e., GG or AG genotype) exhibited significantly higher increases in HDL cholesterol levels. The COX-2 polymorphism had a moderate effect size but made a relatively weak contribution to variations in the HDL cholesterol level (∼9.6 %).
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaProstaglandins, Leukotrienes and Essential Fatty Acids
Brojčani podacivol. 204, 102665
p-ISSN0952-3278
DOIhttps://doi.org/10.1016/j.plefa.2025.102665
URN:NBNurn:nbn:hr:184:570176
Datum objave publikacije2025-04
ProjektŠifra: uniri-biomed-18-251
Naziv (hrvatski): Genetički i biokemijski biljezi metabolizma membranskih fosfolipida i masnih kiselina kao predskazatelji odgovora na antipsihotičnu terapiju u bolesnika s psihotičnom epizodom
Naziv (engleski): Genetic and biochemical markers of the membrane phospholipid and fatty acid metabolism as predictors of treatment response to antipsychotic therapy in patients with psychotic episodes
Voditelj: Alena Buretić-Tomljanović
Pravna nadležnost: Hrvatska
Financijer: Sveučilište u Rijeci
URL dokumentahttps://linkinghub.elsevier.com/retrieve/pii/S095232782500002X
Vrsta resursaTekst
Prava pristupaInstitucijski pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2025-03-11 08:28:19